Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to <5 years and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled trial.

The Introduction and 'Research in context' sections extensively cite prior work on the polio eradication strategy, the safety and immunogenicity data from Phase 1/2 trials in Belgium, Panama, and Bangladesh, and the problem of cVDPV2 outbreaks. The rationale linking the need for improved genetic stability of type 2 OPV to the trial's objectives is clearly stated. Limitations of prior research, such as the lack of data from Africa and the need for lot-to-lot consistency data, are explicitly addressed.

The trial is explicitly described as double-blind and randomised (matching the key criteria for an interventional human study: randomization_method, randomization_unit, blinding_levels, power_analysis, inclusion_exclusion). Randomisation sequences were generated by an independent statistician using permuted block sizes, with a web-based system. Blinding is adequate: only unmasked nurses were aware of the vaccine; parents and all other staff were masked. An a priori power analysis is provided (90% power to show equivalence). Inclusion and exclusion criteria are detailed in the Methods. Pre-specified analysis populations are defined. As per applicability, for a human RCT: replicate_distinction (biological-vs-technical) is not applicable for the primary outcome of seroconversion in individual subjects; controls (positive/negative wet-lab controls) are not applicable as the comparator is bOPV and is assessed via the design; independent_replication (separate replication cohort) is not applicable as this is a pivotal trial. outlier_handling maps to the pre-specified analysis population, which is described (per-protocol, safety, full analysis populations). All applicable sub-criteria are adequate.

Sex is reported for all groups. Age is reported as median (range) for infants and young children. Health status (weight for height Z score) is provided. Race (Black African) and ethnicity (Mandinka, Wolof, etc.) are detailed in demographics. For a human interventional trial, species_strain_source and housing_conditions are not applicable. Sex is not justified because the study enrolled both sexes, making that criterion not applicable.

The paper explicitly names the approving ethics bodies: The Gambia Government and MRC joint ethics committee (ref LEO22052), LSHTM Research Ethics Committee, WIRB-Copernicus Group Institutional Review Board, and the Gambian Medicines Control Agency. Written informed consent from parents is stated. Regulatory compliance with the Declaration of Helsinki and Good Clinical Practice is reported. The trial is registered (PACTR202010705577776). All four human-subject sub-criteria are met.

As a human clinical trial of a drug, the applicable sub-criteria are reagents_identified (the investigational product) and software_tools_identified. nOPV2 and bOPV are identified by manufacturer (PT Biofarma, Bandung, Indonesia), formulation (dose/volume, CCID50), and batch/lot numbers (e.g., 2220720). Statistical software and version are not explicitly named in the main text (the checklist notes it as 'not_reported'), but the analysis methods are described. Other bench-science criteria (antibodies, cell lines, mycoplasma, organisms) are not applicable as the study does not use those resources.

Tests named: 95% Miettinen and Nurminen CIs for rate differences, Exact Clopper-Pearson CIs, bootstrap CIs for medians, maximum likelihood survival methods for GMT, Fisher's exact test for safety events. Exact p-values are reported (e.g., p=0·015, p=0·043). Effect sizes and CIs are reported throughout. The software is not explicitly named, but this is a minor inadequacy. Data presentation includes per-group n, exact CIs, and seroprotection/seroconversion rates with CIs—conventions appropriate for a clinical trial. The mathematical plausibility is confirmed: reported percentages are consistent with given Ns (e.g., 1154/2345 = 49.2%, 296/600=49.3%). The seroconversion rates in Table 2 are all consistent with the reported n/N.

The data sharing section states that IPD (de-identified) will be available from 3 months to 3 years after publication to researchers who provide a scientific proposal and sign a data access agreement. Supporting documents are available on application to the corresponding author. This meets the threshold for reported_and_adequate for data_availability_statement (managed access with mechanism). However, repository_deposit and accession_numbers are not_applicable for identifiable patient data. Code_sharing is not mentioned; the paper does not state whether custom code was used or whether it is available. Therefore, the applicable criteria are data_availability_statement (adequate) and code_sharing (not_reported). Since not all applicable criteria are adequate, the dimension gets a warn.

Methods cover randomisation, blinding, procedures, outcomes, and statistical analysis comprehensively. Trial registration is provided. An explicit reporting guideline is not mentioned (no statement that CONSORT or other checklist was followed), which is a minor gap for a clinical trial. All outcomes described in the methods are reported in the results, including negative/null safety findings. Limitations are discussed (no active type-2 control, rare events undetected). Conclusions do not overclaim: they state the data 'support' licensure, not that the vaccine is definitively effective. Funding (Bill & Melinda Gates Foundation) and COI are declared.